CENTURY THERAPEUTICS INC (IPSC) Stock Fundamental Analysis
NASDAQ:IPSC - Nasdaq - US15673T1007 - Common Stock - Currency: USD
We assign a fundamental rating of 3 out of 10 to IPSC. IPSC was compared to 572 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for IPSC as it has an excellent financial health rating, but there are worries on the profitability. IPSC is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
IPSC had negative earnings in the past year.
IPSC had a negative operating cash flow in the past year.
IPSC had negative earnings in each of the past 5 years.
In the past 5 years IPSC reported 4 times negative operating cash flow.
1.2 Ratios
The Return On Assets of IPSC (-33.42%) is better than 63.72% of its industry peers.
IPSC's Return On Equity of -66.38% is in line compared to the rest of the industry. IPSC outperforms 56.81% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -33.42% | ||
| ROE | -66.38% | ||
| ROIC | N/A |
ROA(3y)-28.9%
ROA(5y)N/A
ROE(3y)-47.14%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
IPSC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
IPSC does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, IPSC has more shares outstanding
There is no outstanding debt for IPSC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -3.03, we must say that IPSC is in the distress zone and has some risk of bankruptcy.
IPSC has a Altman-Z score (-3.03) which is in line with its industry peers.
There is no outstanding debt for IPSC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -3.03 |
ROIC/WACCN/A
WACC9.67%
2.3 Liquidity
IPSC has a Current Ratio of 10.39. This indicates that IPSC is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of IPSC (10.39) is better than 82.12% of its industry peers.
A Quick Ratio of 10.39 indicates that IPSC has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 10.39, IPSC belongs to the top of the industry, outperforming 82.12% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 10.39 | ||
| Quick Ratio | 10.39 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 15.53% over the past year.
Looking at the last year, IPSC shows a small growth in Revenue. The Revenue has grown by 7.83% in the last year.
EPS 1Y (TTM)15.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.73%
Revenue 1Y (TTM)7.83%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%434.46%
3.2 Future
IPSC is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.41% yearly.
Based on estimates for the next years, IPSC will show a very strong growth in Revenue. The Revenue will grow by 97.75% on average per year.
EPS Next Y27.64%
EPS Next 2Y18.77%
EPS Next 3Y4.75%
EPS Next 5Y7.41%
Revenue Next Year89.46%
Revenue Next 2Y58.04%
Revenue Next 3Y1.52%
Revenue Next 5Y97.75%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
IPSC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year IPSC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.77%
EPS Next 3Y4.75%
5. Dividend
5.1 Amount
No dividends for IPSC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CENTURY THERAPEUTICS INC
NASDAQ:IPSC (2/11/2025, 12:21:06 PM)
0.7125
-0.01 (-1.3%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners58.77%
Inst Owner Change-71.32%
Ins Owners3.08%
Ins Owner Change-0.35%
Market Cap60.58M
Analysts84.62
Price Target8.5 (1092.98%)
Short Float %5.02%
Short Ratio4.64
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)19.14%
Min EPS beat(2)19.03%
Max EPS beat(2)19.26%
EPS beat(4)3
Avg EPS beat(4)8.86%
Min EPS beat(4)-14.97%
Max EPS beat(4)19.26%
EPS beat(8)5
Avg EPS beat(8)4.89%
EPS beat(12)7
Avg EPS beat(12)4.74%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-61.27%
Min Revenue beat(2)-61.68%
Max Revenue beat(2)-60.86%
Revenue beat(4)0
Avg Revenue beat(4)-60.45%
Min Revenue beat(4)-85.7%
Max Revenue beat(4)-33.57%
Revenue beat(8)1
Avg Revenue beat(8)-58.27%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-13.79%
PT rev (3m)-18.3%
EPS NQ rev (1m)0%
EPS NQ rev (3m)2.92%
EPS NY rev (1m)0%
EPS NY rev (3m)3.51%
Revenue NQ rev (1m)3.73%
Revenue NQ rev (3m)1.83%
Revenue NY rev (1m)0.01%
Revenue NY rev (3m)-4.04%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 22.56 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.31 | ||
| P/tB | 0.39 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.85
EYN/A
EPS(NY)-1.35
Fwd EYN/A
FCF(TTM)-1.33
FCFYN/A
OCF(TTM)-1.32
OCFYN/A
SpS0.03
BVpS2.3
TBVpS1.85
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -33.42% | ||
| ROE | -66.38% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-28.9%
ROA(5y)N/A
ROE(3y)-47.14%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 10.39 | ||
| Quick Ratio | 10.39 | ||
| Altman-Z | -3.03 |
F-Score5
WACC9.67%
ROIC/WACCN/A
Cap/Depr(3y)555.69%
Cap/Depr(5y)738.07%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.73%
EPS Next Y27.64%
EPS Next 2Y18.77%
EPS Next 3Y4.75%
EPS Next 5Y7.41%
Revenue 1Y (TTM)7.83%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%434.46%
Revenue Next Year89.46%
Revenue Next 2Y58.04%
Revenue Next 3Y1.52%
Revenue Next 5Y97.75%
EBIT growth 1Y-2.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year5%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-297.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-989.29%
OCF growth 3YN/A
OCF growth 5YN/A